Clinical Trial Results:
A multicenter, randomized, controlled study comparing the efficacy and safety of 48 weeks of 40kD branched pegylated interferon alfa-2a (PEGASYS, Ro 25-8310) versus 96 weeks of PEGASYS, alone or in combination with 100 mg lamivudine for 48 weeks in patients with HBeAg-negative chronic hepatitis B.
Summary
|
|
EudraCT number |
2004-002985-39 |
Trial protocol |
IT |
Global completion date |
12 Jan 2010
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
22 Mar 2017
|
First version publication date |
22 Mar 2017
|
Other versions |
|
Summary report(s) |
Clinicaltrials.gov Results Receipt |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.